Europe Preventive Vaccines Market
Europe preventive vaccines market accounted for $10.64 billion in 2020 and will grow by 10.72% an ... Read More
1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 13 1.2.6 Market Size/Share Estimation 14 1.2.7 Research Limitations 15 1.3 Executive Summary 16 2 Market Overview and Dynamics 19 2.1 Market Size and Forecast 19 2.1.1 Impact of COVID-19 on World Economy 21 2.1.2 Impact of COVID-19 on the Market 23 2.2 Major Growth Drivers 25 2.3 Market Restraints and Challenges 28 2.4 Emerging Opportunities and Market Trends 31 2.5 Porter’s Fiver Forces Analysis 35 3 Segmentation of North America Market by Vaccine Type 39 3.1 Market Overview by Vaccine Type 39 3.2 Live/Attenuated Vaccines 41 3.3 Inactivated Vaccines 42 3.4 Subunit Vaccines 43 3.5 Toxoid Vaccines 44 3.6 Conjugate Vaccines 45 3.7 Recombinant Vector Vaccines 46 3.8 Other Vaccines 47 4 Segmentation of North America Market by Disease 48 4.1 Market Overview by Disease 48 4.2 Vaccines for Pneumococcal Disease 50 4.3 Vaccines for Poliovirus 51 4.4 Vaccines for Hepatitis 52 4.5 Vaccines for Influenza 53 4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54 4.7 Vaccines for Varicella 55 4.8 Vaccines for Human Papilloma Virus 56 4.9 Vaccines for COVID-19 57 4.10 Vaccines for Other Diseases 60 5 Segmentation of North America Market by Administration 61 5.1 Market Overview by Administration 61 5.2 Intramuscular Route 63 5.3 Subcutaneous Route 64 5.4 Oral Route 65 5.5 Intravenous Injection 66 5.6 Other Administration Routes 67 6 Segmentation of North America Market by Patient 68 6.1 Market Overview by Patient 68 6.2 Pediatric Vaccines 70 6.3 Adult Vaccines 72 7 North America Market 2020-2026 by Country 74 7.1 Overview of North America Market 74 7.2 U.S. 77 7.3 Canada 82 7.4 Mexico 85 8 Competitive Landscape 88 8.1 Overview of Key Vendors 88 8.2 New Product Launch, Partnership, Investment, and M&A 91 8.3 Company Profiles 92 AstraZeneca plc 92 Bavarian Nordic A/S 95 China National Biotec Group Company Ltd. 98 CSL Ltd. 100 Daiichi Sankyo Co. Ltd 102 Emergent BioSolutions Inc. 104 GlaxoSmithKline plc 106 Johnson & Johnson 110 Merck & Co. 112 Moderna Inc. 114 Novavax, Inc. 115 Pfizer Inc. 117 Sanofi SA 121 Takeda Pharmaceutical Co. Ltd. 123 9 Investing in North America Market: Risk Assessment and Management 125 9.1 Risk Evaluation of North America Market 125 9.2 Critical Success Factors (CSFs) 128 Related Reports and Products 131
Table 1. Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2020-2026 17 Table 2. Growth Rate of World GDP, 2020-2022 22 Table 3. Main Product Trends and Market Opportunities in North America Preventive Vaccines Market 31 Table 4. North America Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 39 Table 5. North America Preventive Vaccines Market by Disease, 2016-2026, $ mn 48 Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021 58 Table 7. North America Preventive Vaccines Market by Administration, 2016-2026, $ mn 61 Table 8. North America Preventive Vaccines Market by Patient, 2016-2026, $ mn 68 Table 9. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71 Table 10. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73 Table 11. North America Preventive Vaccines Market by Country, 2016-2026, $ mn 75 Table 12. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 79 Table 13. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn 79 Table 14. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn 80 Table 15. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 83 Table 16. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn 83 Table 17. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn 84 Table 18. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 86 Table 19. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 86 Table 20. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 87 Table 21. AstraZeneca plc: Company Snapshot 92 Table 22. AstraZeneca plc: Revenue, 2018-2020, $ bn 93 Table 23. Bavarian Nordic A/S: Company Snapshot 95 Table 24. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 96 Table 25. China National Biotec Group Company Ltd.: Company Snapshot 98 Table 26. CSL Ltd.: Company Snapshot 100 Table 27. Daiichi Sankyo Co. Ltd.: Company Snapshot 102 Table 28. Emergent BioSolutions Inc.: Company Snapshot 104 Table 29. GlaxoSmithKline: Company Snapshot 106 Table 30. GlaxoSmithKline: Business Segmentation 107 Table 31. GlaxoSmithKline: Product Portfolio 108 Table 32. GlaxoSmithKline: Revenue, 2018-2020, $ bn 109 Table 33. GlaxoSmithKline: Recent Developments 109 Table 34. Johnson & Johnson: Company Snapshot 110 Table 35. Johnson & Johnson: Business Segments 111 Table 36. Merck & Co., Inc.: Company Snapshot 112 Table 37. Merck & Co., Inc.: Business Segmentation 112 Table 38. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 113 Table 39. Moderna Inc.: Company Snapshot 114 Table 40. Novavax, Inc.: Company Snapshot 115 Table 41. Pfizer Inc.: Company Snapshot 117 Table 42. Pfizer Inc.: Business Segmentation 118 Table 43. Pfizer Inc.: Product Portfolio 119 Table 44. Pfizer Inc.: Revenue, 2018-2020, $ bn 120 Table 45. Pfizer Inc.: Recent Developments 120 Table 46. Sanofi: Company Snapshot 121 Table 47. Sanofi: Business Segmentation 121 Table 48. Sanofi: Revenue, 2018-2020, $ bn 122 Table 49. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 123 Table 50. Risk Evaluation for Investing in North America Market, 2020-2026 126 Table 51. Critical Success Factors and Key Takeaways 129
Figure 1. Research Method Flow Chart 11 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14 Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026 16 Figure 4. North America Preventive Vaccines Market, 2016-2026, $ mn 19 Figure 5. Development Stages of Preventive Vaccines 20 Figure 6. Impact of COVID-19 on Business 23 Figure 7. Primary Drivers and Impact Factors of North America Preventive Vaccines Market 25 Figure 8. Primary Restraints and Impact Factors of North America Preventive Vaccines Market 28 Figure 9. Investment Opportunity Analysis 32 Figure 10. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market 35 Figure 11. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue 40 Figure 12. Contribution to North America 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 40 Figure 13. North America Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 41 Figure 14. North America Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 42 Figure 15. North America Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 43 Figure 16. North America Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 44 Figure 17. North America Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 45 Figure 18. North America Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 46 Figure 19. North America Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 47 Figure 20. Breakdown of North America Preventive Vaccines Market by Disease, 2020-2026, % of Revenue 49 Figure 21. Contribution to North America 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 49 Figure 22. North America Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 50 Figure 23. North America Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 51 Figure 24. North America Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 52 Figure 25. North America Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 53 Figure 26. North America Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 54 Figure 27. North America Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 55 Figure 28. North America Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 56 Figure 29. North America Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 57 Figure 30. North America Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60 Figure 31. Breakdown of North America Preventive Vaccines Market by Administration, 2020-2026, % of Revenue 62 Figure 32. Contribution to North America 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 62 Figure 33. North America Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 63 Figure 34. North America Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 64 Figure 35. North America Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 65 Figure 36. North America Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 66 Figure 37. North America Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 67 Figure 38. Breakdown of North America Preventive Vaccines Market by Patient, 2020-2026, % of Revenue 68 Figure 39. Contribution to North America 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 69 Figure 40. North America Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 70 Figure 41. North America Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 72 Figure 42. Breakdown of North America Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 75 Figure 43. Contribution to North America 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76 Figure 44. U.S. Preventive Vaccines Market, 2016-2026, $ mn 78 Figure 45. Canada Preventive Vaccines Market, 2016-2026, $ mn 82 Figure 46. Preventive Vaccines Market in Mexico, 2016-2026, $ mn 85 Figure 47. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period 88 Figure 48. Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars) 93
Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca plc Bavarian Nordic A/S China National Biotec Group Company Ltd. CSL Ltd. Daiichi Sankyo Co. Ltd Emergent BioSolutions Inc. GlaxoSmithKline plc Johnson & Johnson Merck & Co. Moderna Inc. Novavax, Inc. Pfizer Inc. Sanofi SA Takeda Pharmaceutical Co. Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Europe preventive vaccines market accounted for $10.64 billion in 2020 and will grow by 10.72% an ... Read More
Asia Pacific preventive vaccines market will grow by 13.32% annually with a total addressable mar ... Read More
Global virus filtration market will reach $6,275.3 million by 2026, growing by 12.26% annually ov ... Read More
North America virus filtration market is expected to grow by 11.86% annually in the forecast peri ... Read More